"
Highlights
• Higher doses resveratrol (RSV) are pharmacologically cytotoxic for normal human fibroblasts.
• Low dose RSV ameliorates mitochondrial respiratory dysfunction in patient-derived fibroblasts.
• Low dose RSV also facilitates cellular reprogramming of patient-derived fibroblasts into iPSCs.
Abstract
Mitochondrial disease is associated with a wide variety of clinical presentations, even among patients carrying
heteroplasmic mitochondrial DNA (mtDNA) mutations, probably because of variations in mutant mtDNA proportions at the
tissue and organ levels. Although several case reports and clinical trials have assessed the effectiveness of various
types of drugs and supplements for the treatment of mitochondrial diseases, there are currently no cures for these conditions.
In this study, we demonstrated for the first time that low dose resveratrol (RSV) ameliorated mitochondrial respiratory
dysfunction in patient-derived fibroblasts carrying homoplasmic mtDNA mutations. Furthermore, low dose RSV also facilitated
efficient cellular reprogramming of the patient-derived fibroblasts into induced pluripotent stem cells, partly due to
improved cellular viability. Our results highlight the potential of RSV as a new therapeutic drug candidate
for the treatment of mitochondrial diseases.
"
http://www.sciencedi...567724916300897
